Retroperitoneal Lymphadenectomy for Clinical Stage I Nonseminomatous Testicular Tumor: Laparoscopy Versus Open Surgery and Impact of Learning Curve

1996 ◽  
Vol 156 (1) ◽  
pp. 89-94 ◽  
Author(s):  
Gunter Janetschek ◽  
Alfred Hobisch ◽  
Lorenz Holtl ◽  
Georg Bartsch
1996 ◽  
pp. 89-93 ◽  
Author(s):  
Gunter Janetschek ◽  
Alfred Hobisch ◽  
Lorenz Holtl ◽  
Georg Bartsch

1998 ◽  
Vol 12 (6) ◽  
pp. 561-566 ◽  
Author(s):  
G. GIUSTI ◽  
P. BELTRAMI ◽  
C. TALLARIGO ◽  
G. BIANCHI ◽  
G. MOBILIO

1988 ◽  
Vol 6 (9) ◽  
pp. 1467-1473 ◽  
Author(s):  
C Y Fung ◽  
L A Kalish ◽  
G L Brodsky ◽  
J P Richie ◽  
M B Garnick

A study of 60 patients with clinical stage I nonseminomatous germ cell testicular tumor (NSGCT) was conducted to identify prognostic factors that may predict the likelihood of metastasis. Clinical features and histopathologic features of the primary testicular tumor were examined and analyzed for correlations with the presence of retroperitoneal nodal metastasis documented by surgery (N+) and with development of relapse (R+). Pathologic tumor stage greater than or equal to 2, with tumor extension into the tunica albuginea, rete testis, epididymis, or spermatic cord, was correlated with an increased rate of N+ compared with pathologic tumor stage I (P = .001). Vascular invasion was correlated with a higher rate of N+ (P = .05) and had a similar association with R+ (P = .08). Tumors containing less than 50% teratoma were found to have a higher rate of N+ than tumors with greater than or equal to 50% teratoma (P = .02). Based on the identified prognostic factors, a model for predicting the probability of retroperitoneal nodal metastasis in clinical stage I patients is proposed. The risk factors for nodal metastasis are: pathologic tumor stage greater than or equal to 2, vascular invasion, and less than 50% teratoma. Patients with none of the risk factors are considered at low risk and may be offered orchiectomy alone with surveillance for initial treatment. Patients with all three risk factors are at high risk and should be treated with a retroperitoneal lymph node dissection (RPLND) or possibly chemotherapy. Patients with one or two risk factors are at intermediate risk; it is recommended that they undergo RPLND. This risk model facilitates a rational approach to the management of clinical stage I NSGCT.


2005 ◽  
Vol 173 (4S) ◽  
pp. 116-116
Author(s):  
Makoto Satoh ◽  
Seiichi Saito ◽  
Shigeto Ishidoya ◽  
Akihiro Ito ◽  
Ichiroh Shintaku ◽  
...  

Urology ◽  
1994 ◽  
Vol 44 (3) ◽  
pp. 382-391 ◽  
Author(s):  
Günter Janetschek ◽  
Andreas Reissigl ◽  
Reinhard Peschel ◽  
Alfred Hobisch ◽  
Georg Bartsch

Sign in / Sign up

Export Citation Format

Share Document